The purpose and effect of the proposed rule amendment will be to repeal rules identified during the Department’s comprehensive rule review as duplicative of statute.  

  •  

    DEPARTMENT OF HEALTH

    Prescription Drug Monitoring Program

    RULE NO.:RULE TITLE:

    64K-1.006Program Evaluation and Other

    PURPOSE AND EFFECT: The purpose and effect of the proposed rule amendment will be to repeal rules identified during the Department’s comprehensive rule review as duplicative of statute.

    SUMMARY: Rule 64K-1.006, F.A.C., provides that the department evaluate the prescription drug monitoring program and prepare a report to the Legislature and Governor. This rule is not incorporated by any other rules and its repeal will have no effect no other rules.

    SUMMARY OF STATEMENT OF ESTIMATED REGULATORY COSTS AND LEGISLATIVE RATIFICATION:

    The Agency has determined that this will not have an adverse impact on small business or likely increase directly or indirectly regulatory costs in excess of $200,000 in the aggregate within one year after the implementation of the rule. A SERC has not been prepared by the agency.

    The Agency has determined that the proposed rule is not expected to require legislative ratification based on the statement of estimated regulatory costs or if no SERC is required, the information expressly relied upon and described herein: the SERC checklist does not indicate that the statutory threshold for ratification will be exceeded.

    Any person who wishes to provide information regarding a statement of estimated regulatory costs, or provide a proposal for a lower cost regulatory alternative must do so in writing within 21 days of this notice.

    RULEMAKING AUTHORITY: 893.055 FS.

    LAW IMPLEMENTED: 893.055 FS.

    IF REQUESTED WITHIN 21 DAYS OF THE DATE OF THIS NOTICE, A HEARING WILL BE SCHEDULED AND ANNOUNCED IN THE FAR.

    THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE IS: Rebecca Poston Rebecca.Poston@flhealth.gov, Florida Department of Health, Division of Medical Quality Assurance, 4042 Bald Cypress Way, Bin C-16, Tallahassee, Florida 32399

     

    THE FULL TEXT OF THE PROPOSED RULE IS:

     

    64K-1.006 Program Evaluation and Other.

    Rulemaking Authority 893.055 FS. Law Implemented 893.055 FS. History–New 11-24-11, Repealed_________.

     

    NAME OF PERSON ORIGINATING PROPOSED RULE: Rebecca Poston

    NAME OF AGENCY HEAD WHO APPROVED THE PROPOSED RULE: John H. Armstrong, MD, FACS, Surgeon General and Secretary

    DATE PROPOSED RULE APPROVED BY AGENCY HEAD: November 19, 2013

Document Information

Comments Open:
12/9/2013
Summary:
Rule 64K-1.006 provides that the department evaluate the prescription drug monitoring program and prepare a report to the Legislature and Governor. This rule is not incorporated by any other rules and its repeal will have no effect no other rules.
Purpose:
The purpose and effect of the proposed rule amendment will be to repeal rules identified during the Department’s comprehensive rule review as duplicative of statute.
Rulemaking Authority:
893.055 FS.
Law:
893.055 FS.
Contact:
Rebecca Poston Rebecca.Poston@flhealth.gov, Florida Department of Health, Division of Medical Quality Assurance, 4042 Bald Cypress Way, Bin C-16, Tallahassee, Florida 32399.
Related Rules: (1)
64K-1.006. Program Evaluation and Other